Print this page    •   Back to Web version of article

Medical News
Abbott Hepatitis C Combo Impressive in Small Study

April 6, 2012

A combination of oral hepatitis C drugs being developed by Abbott Laboratories realized cure rates exceeding 90 percent in treatment-naïve patients, according to a small, mid-stage study. The results, released Wednesday, will be presented later this month in Barcelona at a meeting of the European Association for the Study of the Liver.

For 12 weeks, patients in the Phase II trial, known as "Co-Pilot," received Abbott's protease inhibitor ABT-450, boosted by the antiviral drug ritonavir with its polymerase inhibitor ABT-333, and ribavirin, which is used in all current hepatitis C regimens. Patients' blood virus levels were checked 24 weeks later for a sustained virologic response. Those achieving SVR were considered cured.

Eighteen of the 19 patients (95 percent) given 250 milligram doses of ABT-450 in their combination achieved SVR. Thirteen of 14 patients (93 percent) given 150 mg doses of ABT-450 achieved SVR.

"This demonstrates unprecedented cure rates for the most common form of hepatitis C infection," said Scott Brun, Abbott's divisional vice president for infectious disease development. Although confirming the effectiveness and safety of the drugs requires much larger trials, Abbot maintains it is on track to embark on Phase III testing early next year.

In a third portion of the study concentrating on patients unresponsive to the standard regimen of interferon and ribavirin, 8 of 17 (47 percent) achieved SVR. Abbott is hopeful an NS5A inhibitor it is testing in several all-oral combinations will boost SVR rates of previous non-responders.

Back to other news for April 2012

Excerpted from:
04.02.2012; Bill Berkrot

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. You can find this article online by typing this address into your Web browser:

General Disclaimer: is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.